Quantitative Analysis of Favipiravir Spiked in Plasma Using by HPLC

contributed by Shimadzu | 03/02/2021

As of 2020, the development of both pharmaceuticals and vaccines remains urgent to overcome the global coronavirus disease 2019 (COVID-19) pandemic. Favipiravir (brand name: Avigan^®), a promising drug candidate for COVID-19, is classified as an antiinfluenza drug, evaluated and developed for both novel and re-emerging influenza viruses. (1), (2) Favipiravir undergoes renal excretion, eliminated in the urine mainly as a hydroxide. Notably, the plasma levels of this drug are difficult to control owing to its once daily dosing regimen. (3) Consequently, the accurate monitoring of drug levels is crucial.

Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE!

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

Receive communication from The Cannabis Scientist I want to stay up to date with the Mass Spectrometry field I want to stay up to date with the Spectroscopy field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.